

SEP 24 2002

TECH CENTER 1608/2900 1 of 6

SEP 20 2002

FORM PTO 1449  
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baidur, Stephanie Beigel-Orme,  
Paul O. Sheppard

Filing Date:  
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JSP	A1	95/32287	11/30/95	PCT		
	A2	99/06554	02/11/99	PCT		
	A3	00/07612	02/17/00	PCT		
	A4	00/46245	08/10/00	PCT		
	A5	01/42467	06/14/00	PCT		
	A6	02/04487	01/17/02	PCT		
	A7	02/40512	05/23/02	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

JSP	A8	Jia et al., "Discovery of new human beta-defensins using a genomics-based approach," <u>Gene</u> , 263(1-2):211-218 (Jan. 2001).
	A9	Lehrer et al. "Defensins: antimicrobial and cytotoxic peptides of mammalian cells," <u>Annu Rev Immunol.</u> , 11:105-128 (1993). Review.
	A10	Harder et al. "A peptide antibiotic from human skin," <u>Nature</u> , 387(6636):861 (June 26, 1997).
	A11	Incyte Pharmaceuticals, Inc. clone, 1996:INC1433022.
JSP	A12	Incyte Pharmaceuticals, Inc. LIBRARY, 1996:BEPINON01.

Examiner

Date considered

11/19/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 2 of 6

 FORM 1449  
(REV 2-32)

 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):

 David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. Sheppard

Filing Date:

March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
						RECEIVED
						SEP 24 2002

## FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

TECH CENTER 1600/2900

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

A13	Incyte Pharmaceuticals, Inc. LIBRARY, 1996: LPARNOT02.
A14	Selsted et al., "Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils," <i>J Biol Chem.</i> , 268(9):6641-6648 (March 25, 1993).
A15	Bensch et al., "hBD-1: a novel beta-defensin from human plasma," <i>FEBS Lett.</i> , 368(2):331-335 (July 17, 1995).
A16	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> , 247(4948):1306-1310 (March 16, 1990).
A17	Wells, J.A., "Additivity of mutational effects in proteins," <i>Biochemistry</i> , 29(37):8509-8517 (Sept. 18, 1990).
A18	Liu et al., "Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation," <i>Gene</i> , 222(2):237-244 (Nov. 19, 1998).
A19	Porter et al., "Broad-spectrum antimicrobial activity of human intestinal defensin 5," <i>Infect Immun.</i> , 65(6):2396-2401 (June 1997).
A20	Daher et al., "Direct inactivation of viruses by human granulocyte defensins," <i>J Virol.</i> , 60(3):1068-1074 (Dec. 1986).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 3 of 6

TECH CENTER 1600/2900

SEP 24 2002

**FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE  
(REV 2-32) PATENT AND TRADEMARK OFFICE****INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

File No. 97-44D1

Serial No.  
10/091,166Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A21		Martin et al., "Defensins and other endogenous peptide antibiotics of vertebrates," <u>J Leukoc Biol.</u> , 58(2):128-136 (Aug. 1995). Review.
	A22		Ouellette et al., "Paneth cell defensins: endogenous peptide components of intestinal host defense," <u>FASEB J.</u> , 10(11):1280-1289 (Sept. 1996). Review.
	A23		Lichtenstein et al., "In vitro tumor cell cytotoxicity mediated by peptide defensins of human and rabbit granulocytes," <u>Blood</u> , 68(6):1407-1410 (Dec. 1986).
	A24		Zhu et al., "Isolation and structure of corticostatin peptides from rabbit fetal and adult lung," <u>Proc Natl Acad Sci U S A.</u> , 85(2):592-596 (Jan. 1988).
	A25		Territo et al., "Monocyte-chemotactic activity of defensins from human neutrophils," <u>J Clin Invest.</u> , 84(6):2017-2020 (Dec. 1989).
	A26		Tamura et al., "A marked decrease in defensin mRNA in the only case of congenital neutrophil-specific granule deficiency reported in Japan," <u>Int J Hematol.</u> , 59(2):137-142 (Feb. 1994).
	A27		Higazi et al., "Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells," <u>J Biol Chem.</u> , 271(30):17650-5 (July 26, 1996).
	A28		Yang et al., "Mammalian defensins in immunity: more than just microbicidal," <u>Trends Immunol.</u> , 23(6):291-6 (June 2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

SEP 24 2002

TECH CENTER 1600/2900 6

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE  
(REV 2-32) PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):

David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. Sheppard

Filing Date:

March 5, 2002

Group: 1653



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A29		Circo et al., "Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism," <u>Biochem Biophys Res Commun.</u> , 293(1):586-92 (April 26, 2002).
	A30		Schibli et al., "The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus," <u>J Biol Chem.</u> , 277(10):8279-89 (March 8, 2002).
	A31		Harder et al., "Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic," <u>J Biol Chem.</u> , 276(8):5707-13 (Feb. 23, 2001).
	A32		Goldman et al., "Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis," <u>Cell</u> , 88(4):553-60 (Feb. 21, 1997).
	A33		Smith et al., "Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid," <u>Cell</u> , 85(2):229-36 (April 19, 1996).
↓	A34		Davies et al., "CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium," <u>Am J Respir Cell Mol Biol.</u> , 16(6):657-63 (June 1997).
	A35		Dunsche et al., "The novel human beta-defensin-3 is widely expressed in oral tissues," <u>Eur. J. Oral. Sci.</u> , 109:121-124 (2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 24 2002

TECH CENTER 1600/2900

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE  
(REV 2-32) PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

A36		Cullor et al., "In vitro antimicrobial activity of defensins against ocular pathogens," <u>Arch Ophthalmol.</u> , 108(6):861-864 (June 1990).
A37		Schwab et al., "Corneal storage medium preservation with defensins," <u>Cornea</u> , 11(5):370-375 (Sept. 1992).
A38		Yeh et al., "Single-dose pharmacokinetics of indinavir and the effect of food," <u>Antimicrob Agents Chemother.</u> , 42(2):332-338 (Feb. 1998).
A39		Haynes et al., "Innate defence of the eye by antimicrobial defensin peptides," <u>Lancet</u> , 352(9126):451-452 (Aug. 8, 1998).
A40		Haynes et al., "Antimicrobial defensin peptides of the human ocular surface," <u>Br J Ophthalmol.</u> , 83(6):737-41 (June 1999).
A41		Sawicki et al., "Contraceptive potential of peptide antibiotics," <u>Lancet</u> , 353(9151):464-5 (Feb. 6, 1999).
A42		Garcia et al., "Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of <i>Xenopus</i> oocytes and the induction of macrophage chemoattraction," <u>Cell Tissue Res.</u> , 306(2):257-64 (Nov. 2001).

Examiner

Date considered

11/19/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 24 2002

TECH CENTER 1609/2900 6 of 6

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A43	Zasloff, M., "Antimicrobial peptides of multicellular organisms," <u>Nature</u> , 415:389-395 (Jan. 2002).
	A44	Krisanaprakornkit et al., "Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family," <u>J Immunol.</u> 168(1):316-324 (Jan. 1, 2002).
	A45	Garcia et al., "Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity," <u>FASEB J.</u> , express article 10.1096/fj.00-0865fje, published online on June 18, 2001.
	A46	Duits et al., "Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids," <u>Biochem Biophys Res Commun.</u> 280(2):522-525 (Jan. 2001).
	A47	Hancock et al., "Antibiotic resistance in <i>Pseudomonas aeruginosa</i> : mechanisms and impact on treatment," <u>Drug Resist Updat.</u> 3(4):247-255 (Aug. 2000).
	A48	Biragyn et al., "DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses," <u>Blood</u> , 100(4):1153-1159 (Aug. 15, 2002).

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.